A PHASE 2 OPEN-LABEL, MULTICENTER CLINICAL STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETIC, AND PHARMACODYNAMIC PROFILES OF CGT9486 AS A SINGLE AGENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

Registry ID

CGT9486-20-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

COGENT BIOSCIENCES, INC.

Start date

2025-04-22

Last update

2021-06-28

Conditions

• MASTOCYTOSIS

Related clinical trials

• AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY IN PATIENTS WHO PARTICIPATED IN AN AVAPRITINIB CLINICAL STUDY
• (SUMMIT) A MULTI-PART, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY OF THE SAFETY AND EFFICACY OF CGT9486 IN SUBJECTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

View on source registry